



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/550,295	Marie-Anne Petit	0508-1140

466  
YOUNG & THOMPSON  
745 SOUTH 23RD STREET  
2ND FLOOR  
ARLINGTON, VA 22202

INTERNATIONAL APPLICATION NO.

PCT/EP04/03412

I.A. FILING DATE	PRIORITY DATE
03/31/2004	04/01/2003

CONFIRMATION NO. 2042

## 371 FORMALITIES LETTER



\*OC000000019973105\*

Date Mailed: 08/10/2006

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Priority Document
- Copy of the International Application filed on 09/21/2005
- Copy of the International Search Report filed on 09/21/2005
- Preliminary Amendments filed on 09/21/2005
- Information Disclosure Statements filed on 09/21/2005
- Biochemical Sequence Diskette filed on 07/10/2006
- Oath or Declaration filed on 02/23/2006
- Biochemical Sequence Listing filed on 07/10/2006
- Request for Immediate Examination filed on 09/21/2005
- U.S. Basic National Fees filed on 09/21/2005
- Priority Documents filed on 09/21/2005

Applicant's response filed 07/10/2006 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 05/09/2006 have not been completed.

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

KAREN M WILLIAMS

---

Telephone: (703) 308-9140 EXT 213

**PART 1 - ATTORNEY/APPLICANT COPY**

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/550,295	PCT/EP04/03412	0508-1140

FORM PCT/DO/EO/916 (371 Formalities Notice)

1614/IFXp



PATENT  
0508-1140

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Marie-Anne PETIT et al. Conf. 2042

Application No. 10/550,295

Filed September 21, 2005

ANTIBODIES DIRECTED AGAINST HEPATITIS  
C VIRUS E1E2 COMPLEX, COMPOSITIONS OF  
HCV PARTICLES, AND PHARMACEUTICAL COMPOSITIONS

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE**

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

September 7, 2006

Sir:

In response to the Notification of Defective Response mailed on August 10, 2006, please amend the record of the above-identified application as follows:

**Remarks** begin on page 2 of this paper.

An **Appendix** is attached following the signature page of this paper.

REMARKS

Responsive to the requirement for submission of a sequence listing imposed in the Notification of Defective Response, the same is provided herewith, attached to the present amendment, in paper and disk formats. Applicants hereby state that the attached paper and computer-readable copies have the same content, and introduce no new matter into the present specification.

In view of the above, it is respectfully submitted that the above-identified application complies with the requirements for patents applications containing nucleotide sequences and/or amino acid sequence disclosures.

Favorable consideration of this application is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON

  
Philip Dubois, Reg. No. 50,696  
745 South 23<sup>rd</sup> Street  
Arlington, VA 22202  
Telephone (703) 521-2297  
Telefax (703) 685-0573  
(703) 979-4709

PD/lk

**APPENDIX:**

The Appendix includes the following items:

- sequence listing in computer and paper formats